Rezolute(US:RZLT) TMX Newsfile·2026-01-18 12:41Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following significant losses in its stock [2][4] - Rezolute's shares experienced a sharp decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug [5] - The clinical trial failed to meet both primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [5] Group 2 - Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4] - The firm encourages investors who suffered losses in Rezolute stock or options to discuss their legal rights directly with their attorneys [1]